Active raiseSeries B+ open · $50M target to advance pivotal PTSD trial · Q1 2027 initiation
Investors · Series B+
In March 2026, Otsuka acquired Transcend Therapeutics for $1.225B — $700M upfront — for a Phase 2 PTSD asset with no approved product. In 2021, Jazz acquired GW Pharmaceuticals for $7.2B on the strength of Epidiolex®. Ananda sits at the intersection of both theses: Phase 2 PTSD data and a Nantheia™ CBD platform with composition-of-matter IP through 2044.
Investment thesis
Invented at Hebrew University and exclusively licensed to Ananda — a delivery technology that produces shorter Tmax, higher Cmax, dose linearity at 200/400 mg, no food effect, and a coefficient of variation ~75% (vs ~308% for Epidiolex®). Composition-of-matter patents in 30+ jurisdictions; expiry 09/2037 with optimization patents pending to 2044.
13M Americans live with PTSD ($16B global market, $8.4B US). The only FDA-approved monotherapies are sertraline (1999) and paroxetine (2001) — SSRIs with a 37–62% response rate per FDA labeling. Phase IIa data supports a program now in five Phase 2 trials.
Five Phase 2 trials underway, with investigator-sponsored work supported by NIH and other agencies. $35M raised since inception; $17M in grants directed to investigators. PCAOB-audited financials 2017–2024.
Comparable transactions
The market has answered the value question for both halves of Ananda's profile — Phase 2 PTSD assets without an approved product, and pharmaceutical CBD platforms — within the last five years.
Otsuka paid $700M cash upfront for a single Phase 2 PTSD asset with no approved product and no pivotal data — a clean floor for derisked Phase 2 PTSD efficacy in 2026, at exactly the inflection Ananda reaches with our Q2 readout.
SOURCE: OTSUKA PHARMACEUTICAL 8-K · 03/2026
Jazz paid $7.2B for a single-product company built on Epidiolex — a CBD oral approved only for narrow orphan epilepsies. Ananda's Nantheia™ is composition + delivery, with IP through 2044, targeting two dramatically larger markets — PTSD and OUD.
SOURCE: JAZZ PHARMACEUTICALS PRESS RELEASE · 02/2021
The set-up · Both theses. One company.
Transcend was acquired for $1.225B with PTSD Phase 2 data and nothing else. GW was acquired for $7.2B with one product approved only for narrow orphan epilepsies. Ananda has five Phase 2 trials across PTSD, SAD, OUD, and smoking cessation — every program on the same Nantheia™ composition, with IP through 2044. $50M secures the pivotal trial that converts these comparables into our exit.
Use of proceeds
Round terms
Indicative terms. Detailed deck under CDA.
Catalyst calendar
| Date | Event | Type |
|---|---|---|
| Q1 2026 | NYU Phase IIa SAD readout (N=60) — available under CDA | COMPLETED |
| Q2 2026 | NYU Langone Phase II PTSD readout (N=85) | TIER-1 READOUT |
| Q2 2026 | Nebraska Phase II PTSD interim readout | INTERIM |
| Q4 2026 | UCLA Smoking Cessation Phase II final readout | READOUT |
| Q4 2026 | FDA Pivotal Trial Initiation Meeting | REGULATORY |
| Q1 2027 | Multi-center pivotal PTSD trial initiation (N=350) | TRIAL START |
| Q1 2027 | Nebraska Phase II PTSD final readout (N=140) | READOUT |
| Q1 2027 | Yale Phase II OUD readout (N=120) | READOUT |
| Q3 2028 | Pivotal PTSD trial readout (N=350) | PIVOTAL READOUT |
| Q4 2028 | NDA filing with FDA | FILING |
| Q4 2029 | PTSD product launch | APPROVAL |
Investor materials
Investor deck, full Phase I PK, IND package, pivotal trial protocol, and CMC summary available under signed CDA to qualified institutional investors. Data room access requires an executed confidential disclosure agreement.
Direct contact
www.anandascientific.com
